-
1 Comment
Zhejiang Hisoar Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 8.6% below its 200 day moving average.
From a valuation standpoint, the stock is 32.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.5.
Zhejiang Hisoar Pharmaceutical Co., Ltd's total revenue rose by 0.1% to $644M since the same quarter in the previous year.
Its net income has dropped by 50.4% to $96M since the same quarter in the previous year.
Finally, its free cash flow grew by 64.0% to $155M since the same quarter in the previous year.
Based on the above factors, Zhejiang Hisoar Pharmaceutical Co., Ltd gets an overall score of 3/5.
| CurrencyCode | CNY |
|---|---|
| ISIN | CNE000001PY2 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | SHE |
| Target Price | 28.3 |
|---|---|
| Market Cap | 8B |
| PE Ratio | None |
| Beta | 0.56 |
| Dividend Yield | None |
Zhejiang Hisoar Pharmaceutical Co., Ltd. operates as a pharmaceutical company in China and internationally. The company offers antibiotics, cardiovascular products, hypoglycemic products, fine chemicals, dyes, intermediates, and other products, as well as clindamycin products. It also provides pharmaceutical, dyestuff, and other related services. The company was founded in 1966 and is based in Taizhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002099.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
